outpatient dosing of bispecific antibodies: what do clinicians need to consider?
Published 4 months ago • 103 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
2:02
rwd from insight-mm: duration of therapy and treatment sequencing
-
3:10
the importance of nutrition in hematology and cancer care
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
0:41
isct in bringing together the scientific community
-
1:47
shared treatment decision-making
-
4:36
being marilyn…with myelofibrosis—an mf journey
-
4:02
why is water so important to the tech industry?
-
8:11
what is hematology oncology?
-
5:06
considerations for drug development in hematological oncology
-
1:11
making clinical decisions with patients
-
42:15
is your lab ready for fda ldt oversight? | a healthrecon webinar
-
4:22
management of acute gvhd
-
1:20
to jaki or not to jaki - treating early mf
-
5:07
daratumumab in the management of al amyloidosis
-
0:51
challenges in managing myeloma patients
-
4:31
mpns at eha 2020: what to look out for
-
6:33
mrd as a tool to discontinue therapy in mm?
-
2:31
management of all patients during covid-19
-
8:34
hct in mds: cell source and conditioning type
-
6:28
outcomes following first-line therapy in routine clinical practice in alcl
-
3:22
chromothripsis and chromoplexy in myeloma
-
0:54
the positives of virtual hemonc meetings